IVD Medical (1931) H1 2026 earnings summary

Executive summary

• Revenue rose 6.6% year-over-year to RMB1,353.7 million, mainly due to the acquisition and consolidation of B-Soft Co., Ltd.

• The group reported a net loss of RMB182.3 million, a significant reversal from a profit of RMB38.3 million in the prior year period.

• Loss attributable to owners was RMB70.5 million, compared to a profit of RMB39.1 million last year.

• Adjusted (non-GAAP) loss for the period was RMB184.6 million, reflecting higher operating and financing costs.

Financial highlights

• Gross profit increased 6.4% to RMB297.4 million; gross margin remained stable at 22.0%.

• EBITDA turned negative at RMB-32.1 million, down from RMB113.8 million a year ago.

• Net loss margin was -13.5% versus a net profit margin of 3.0% last year.

• Cash and cash equivalents rose 48.2% to RMB520.1 million.

• Total assets increased 149% to RMB14.8 billion, mainly from the B-Soft acquisition.

Outlook and guidance

• Plans to expand product portfolio, distribution network, and hospital coverage to capture IVD market growth.

• Focus on upgrading solution services with data-driven and automated tools for clinical labs.

• Intends to accelerate R&D in mass spectrometry, molecular diagnostics, and AI-driven technologies.

• Exploring AI robotics for industrial automation and healthcare applications.